ctDNA-Guided Surveillance Doubles Curative Treatment Rate for Recurrent CRC

◆ TRIAL DATA

In the phase III FIND trial, patients monitored with circulating tumor DNA testing after surgery were twice as likely to receive curative-intent treatment when cancer recurred compared to standard surveillance (48.1% vs 23.6%). (The ASCO Post)